title: Influence of p-coumaric acid on doxorubicin-induced oxidative stress in rat's heart.
abstract: The therapeutic value of doxorubicin (DOX) as anticancer antibiotic is limited by its cardiotoxicity. The implication of natural phenolic acids in the prevention of many pathologic diseases has been reported. Herein, the ability of p-coumaric (PC) acid, a member of phenolic acids, to protect rat's heart against DOX-induced oxidative stress was investigated. Three main groups of albino rats were used; DOX, PC, and PC plus DOX-receiving animals. Corresponding control animals were also used. DOX was administered i.p. in a single dose of 15mgkg(-1). PC alone, in a dose of 100mgkg(-1), was orally administered for five consecutive days. In PC/DOX group, rats received PC 5 days prior to DOX. DOX-induced high serum levels of lactic dehydrogenase (LDH) and creatine phosphokinase (CPK), were reduced significantly by PC administration, compared to DOX-receiving rats. Pretreatment with PC ameliorated the cardiac content of glutathione (GSH), and superoxide dismutase (SOD) & catalase (CAT) activities, compared to DOX-receiving rats. On the other hand, accumulation of cardiac content of MDA significantly decreased following PC pretreatment, compared to DOX-treated rats. The data presented here indicate that PC protects rats hearts against DOX-induced oxidative stress in the heart. It may be worthy to consider the usefulness of PC as adjuvant therapy in cancer management.
authors.affiliation: Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. elmahdym@hotmail.com
authors.forename: M H
authors.initials: MH
authors.lastname: Abdel-Wahab
authors.forename: M A
authors.initials: MA
authors.lastname: El-Mahdy
authors.forename: M F
authors.initials: MF
authors.lastname: Abd-Ellah
authors.forename: G K
authors.initials: GK
authors.lastname: Helal
authors.forename: F
authors.initials: F
authors.lastname: Khalifa
authors.forename: F M A
authors.initials: FM
authors.lastname: Hamada
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D003373:Coumaric Acids / Q000494:pharmacology*; D003402:Creatine Kinase / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008315:Malondialdehyde / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D010084:Oxidation-Reduction; D018384:Oxidative Stress / Q000187:drug effects*; D011422:Propionates; D011506:Proteins / Q000378:metabolism; D051381:Rats; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D000975:Antioxidants; D003373:Coumaric Acids; D011422:Propionates; D011506:Proteins; D008315:Malondialdehyde; D004317:Doxorubicin; D007770:L-Lactate Dehydrogenase; D002374:Catalase; D013482:Superoxide Dismutase; D003402:Creatine Kinase; D005978:Glutathione; C495469:p-coumaric acid